

REMARKS

Claims 1-20 are pending in the application. Claims 1-20 are hereby canceled and new claims 21-38 are added. Support for new claims 21-38 is detailed in the table below.

New Claim Number	Support in the Specification
21, 23, 29, 32, 33	Original claim 7
22	Page 24, lines 32-34
24	Page 25, line 28 through page 26, line 5
25, 26	Page 26, lines 6-19
27, 28	Page 8, lines 1-36; and page 9, lines 1-34
30, 31	Page 24, line 37 through page 25, line 4
34	Page 25, lines 5-11
35	Page 59, line 6 through page 60, line 8
36	Page 69, line 19 through page 70, line 34
37	Original claim 8
38	Page 409, lines 4-11

The Specification is amended to: provide a descriptive title, update the patent family status of the present application, and comply with the sequence rules.

Applicants believe no new matter is added by the foregoing amendments.

I. Miscellaneous Issue

The Applicants respectfully bring the Examiner's attention to page 2 of the present Office Action. The Examiner states that claims 21-30 are pending in the current application. Applicants records do not indicate that claims 1-20 were ever canceled prior to the current amendment and response. Applicants also checked with PAIR and confirm that the originally filed claims were not previously canceled. The transaction history print out is attached for the Examiner's convenience. Applicants respectfully request that the Examiner confirm that originally filed claims 1-20 were not previously canceled. Applicants are proceeding to respond to the current office action presuming that original claims 1-20 have not been canceled previously.

II. Restriction Requirement

Applicants note that the Examiner found that examining binding compounds that bind to human and mouse DAP12 proteins would not be a serious burden. Applicants thank the Examiner for rejoining these two groups.

III. Objections to the Specification

The Examiner objected to the specification for the following reasons: failure to comply with the sequence rules, the requirement of a descriptive title, and the need to update the priority claim. Applicants have amended the specification above to address these issues, and believe the objections are now moot. Withdrawal of these objections is respectfully requested.

IV. Information Disclosure Statement

The Examiner noted that the specification contains a list of references that are not identified in the Information Disclosure Statement which was submitted on June 23, 2004. Applicants cannot identify such a list in the specification and respectfully request that the Examiner point out where this list appears. Applicants will correct any such oversight upon notice.

V. Objection to the Claims

The Examiner objected to claims 7-9 as being drawn to non-elected inventions. Claims 7-9 are canceled and the objection is therefore moot as to these claims. Applicants submit that new claims 21-38 are free from this rejection. In view of the foregoing, withdrawal of this objection to claims 7-9 is respectfully requested.

VI. Rejection of Claims 7-9 under 35 U.S.C. 112, Second Paragraph

The Examiner rejected claims 7-9 under 35 U.S.C. 112, second paragraph, on the basis that claims 7-9 are indefinite. Claims 7-9 are canceled and the rejection is therefore moot as to these claims.

Applicants submit that new claims 21-38 are free from this rejection. In view of the foregoing, withdrawal of this rejection is respectfully requested.

Conclusion

Applicants' current response is believed to be a complete reply to all the outstanding issues of the latest Office action. Further, the present response is a bona fide effort to place the application in condition for allowance or in better form for appeal.

Accordingly, Applicants respectfully request reconsideration and passage of the amended claims to allowance at the earliest possible convenience.

Applicant believes that no additional fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

If the Examiner believes that a telephonic conference would aid the prosecution of this case in any way, please call the undersigned.

Respectfully submitted,

Date: 30 April 2007

By: /Sheela Mohan-Peterson/
Sheela Mohan-Peterson, Reg. No. 41,201
Attorney for Applicants

Customer No. 028008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

Enclosure: PAIR Transaction History

Transaction History

Date	Transaction Description
11-29-2006	Mail Non-Final Rejection
11-27-2006	Non-Final Rejection
06-23-2004	Information Disclosure Statement considered
09-30-2006	Date Forwarded to Examiner
09-27-2006	Response to Election / Restriction Filed
08-29-2006	Mail Restriction Requirement
08-28-2006	Requirement for Restriction / Election
06-23-2004	Reference capture on IDS
06-23-2004	Information Disclosure Statement (IDS) Filed
04-29-2004	IFW TSS Processing by Tech Center Complete
04-29-2004	Case Docketed to Examiner in GAU
04-01-2004	Application Return from OIPE
04-01-2004	Application Return TO OIPE
03-31-2004	Application Dispatched from OIPE
04-01-2004	Application Is Now Complete
03-30-2004	Cleared by L&R (LARS)
03-18-2004	Referred to Level 2 (LARS) by OIPE CSR
03-02-2004	IFW Scan & PACR Auto Security Review
02-26-2004	CRF Is Good Technically / Entered into Database
02-10-2004	CRF Disk Has Been Received by Preexam / Group / PCT
02-10-2004	Initial Exam Team nn

Close Window